RxDoctor Payments Data

Eitan Klein, MD

Cardiovascular Disease · New York, NYNPI 1568662450

Payments from drug & device makers

$582in general payments, 2019–2025

Across 32 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$101
  • Boston Scientific$79
  • E.r. Squibb & Sons, L.L.C.$73
  • Novartis$71
  • Biobeat USA Inc.$43
  • Boehringer Ingelheim$42
  • plus $174 from 7 others

What the payments were for

  • Food & beverage$582100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$582 in reported general payments places this provider in the 30th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$257,792
Medicare patients
1,619
Services billed
4,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban357$378,797
Repatha SureclickEvolocumab102$84,322
EntrestoSacubitril/Valsartan35$46,345
Praluent PenAlirocumab63$36,461
JardianceEmpagliflozin30$36,269
TrulicityDulaglutide18$23,911
XareltoRivaroxaban15$17,719
MultaqDronedarone Hcl12$11,937
Nebivolol Hcl122$10,735
JanumetSitagliptin Phos/Metformin Hcl13$8,002
Rosuvastatin Calcium540$7,452
Ezetimibe220$7,351
Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid11$5,501
Metoprolol Succinate254$4,186
Valsartan152$4,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$378,797357 claims
NovartisEntresto$71$46,34535 claims
Boehringer IngelheimJardiance$42$36,26930 claims
Johnson & JohnsonXarelto$15$17,71915 claims
Sanofi-aventis U.S. LLCMultaq$23$11,93712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →